All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-06-23T09:51:59.000Z

Genomics of high-risk myeloma

Jun 23, 2020
Share:

Bookmark this article

During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM.

Genomics of high-risk myeloma

Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed:

  1. Who is high risk?
  2. What are the characteristics of high-risk MM?
  3. How do we treat patients with high-risk disease?


Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox